Amylin Pharmaceuticals to Present at the 18th Annual Credit Suisse Healthcare Conference

Amylin Pharmaceuticals to Present at the 18th Annual Credit Suisse Healthcare
Conference

SAN DIEGO, Nov. 5, 2009 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc.
(Nasdaq: AMLN) will be presenting at the 18th Annual Credit Suisse Healthcare
Conference in Phoenix, Arizona on Wednesday, November 11, 2009 at 10:00 a.m.
PT / 1:00 p.m. ET. Mark Foletta, senior vice president of finance and chief
financial officer at Amylin Pharmaceuticals, will be providing a corporate
overview.

The audio portion of the presentation will be webcast and a recording will be
made available following the event. The webcast and recording will be
accessible through Amylin's corporate Web site, located at www.amylin.com. To
access the live webcast, please log on to Amylin's site approximately fifteen
minutes prior to the presentation to register and download any necessary audio
software.

About Amylin Pharmaceuticals
Amylin Pharmaceuticals is a biopharmaceutical company dedicated to improving
lives of patients through the discovery, development and commercialization of
innovative medicines. Amylin has developed and gained approval for two
first-in-class medicines for diabetes, SYMLIN® (pramlintide acetate) injection
and BYETTA® (exenatide) injection. Amylin's research and development
activities leverage the Company's expertise in metabolism to develop potential
therapies to treat diabetes and obesity. Amylin is headquartered in San Diego,
California. Further information about Amylin Pharmaceuticals is available at
www.amylin.com.

SOURCE Amylin Pharmaceuticals, Inc.

Financial, Michael York, Senior Director, Investor Relations, +1-858-458-8602,
michael.york@amylin.com, or Media, Anne Erickson, Senior Director, Corporate
Affairs, +1-858-754-4443, anne.erickson@amylin.com, both of Amylin
Pharmaceuticals, Inc.